echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Antitumor Therapy > Br J Cancer: The relationship between FGFR3 gene changes and immune checkpoint inhibitor response in metastatic urothelial carcinoma: a real-world study

    Br J Cancer: The relationship between FGFR3 gene changes and immune checkpoint inhibitor response in metastatic urothelial carcinoma: a real-world study

    • Last Update: 2021-07-30
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Urothelial carcinoma (UC) with FGFR3 gene alteration is associated with a non-T cell inflammatory phenotype and therefore is considered to be less responsive to immune checkpoint block (ICB)


    Urothelial carcinoma (UC) with FGFR3 gene alteration is associated with a non-T cell inflammatory phenotype and therefore is considered to be less responsive to immune checkpoint block (ICB)


    109 patients received single-drug PD1 or PD-L1 inhibitor treatment, 108 patients could be evaluated for efficacy, and 103 patients could be subjected to somatic cell sequencing of FGFR3 gene changes


    109 patients received single-drug PD1 or PD-L1 inhibitor treatment, 108 patients could be evaluated for efficacy, and 103 patients could be subjected to somatic cell sequencing of FGFR3 gene changes


    The median OS of FGFR3 genetically altered patients and FGFR3 wild-type patients were 9.



     Prognosis

    There was no significant difference in the median duration of response between FGFR3 genetically altered patients and FGFR3 wild-type patients, which were 15.


    There was no significant difference in the median duration of response between FGFR3 genetically altered patients and FGFR3 wild-type patients, which were 15.



     Efficacy evaluation

    The FGFR3 RNA level of FGFR3 gene alteration patients is higher than that of wild-type patients, and the FGFR3 gene mutation and fusion FGFR3 RNA level are similar


    The FGFR3 RNA level of FGFR3 gene alteration patients is higher than that of wild-type patients, and the FGFR3 gene mutation and fusion FGFR3 RNA level are similar



    Signal pathway changes

    And according to criteria different subtypes, FGFR3 gene changes mainly in the luminal and luminal- papillary subtype, and is also found to FGFR3 RNA with high expression levels


    And according to criteria different subtypes, FGFR3 gene changes mainly in the luminal and luminal- papillary subtype, and is also found to FGFR3 RNA with high expression levels



    Comparison of different subtypes

    In summary, metastatic urothelial carcinoma (UC) with FGFR3 gene alteration has no effect on the immune checkpoint block (ICB) response, and does not affect the patient's prognosis


    In summary, metastatic urothelial carcinoma (UC) with FGFR3 gene alteration has no effect on the immune checkpoint block (ICB) response, and does not affect the patient's prognosis
    .
    Metastatic urothelial carcinoma (UC) with FGFR3 gene alteration has no effect on the immune checkpoint block (ICB) response, and does not affect the patient's prognosis
    .
    Metastatic urothelial carcinoma (UC) with FGFR3 gene alteration has no effect on the immune checkpoint block (ICB) response, and does not affect the patient's prognosis
    .

    Original source:

    Original source:

    Rose TL, Weir WH, Mayhew GM, et al.
    Fibroblast growth factor receptor 3 alterations and response to immune checkpoint inhibition in metastatic urothelial cancer: a real world experience.
    Br J Cancer.
    2021 Jul 22.
    doi: 10.
    1038/s41416-021- 01488-6.
    Epub ahead of print.
    PMID: 34294892.

    Rose TL, Weir WH, Mayhew GM, et al.
    Fibroblast growth factor receptor 3 alterations and response to immune checkpoint inhibition in metastatic urothelial cancer: a real world experience.
    Br J Cancer.
    2021 Jul 22.
    doi: 10.
    1038/s41416-021- 01488-6.
    Epub ahead of print.
    PMID: 34294892.


    Leave a message here
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.